How we work with industry partners
At Amyloidosis UK, we choose to engage with the pharmaceutical and medical device industries because we share common goals: raising awareness of amyloidosis, educating healthcare professionals, and improving access to diagnosis, care, and treatment.
Some of our industry partners also manufacture medicines or devices used by people with amyloidosis. We recognise that this has the potential to create conflicts of interest and are committed to managing these relationships with transparency and integrity.
To mitigate any potential conflicts, we adhere to the following principles:
To mitigate any potential conflicts, we adhere to the following principles:
Independence: We only accept financial support from industry when there is no attempt to influence the charity’s policies, direction, or services.
Strategic Alignment: Industry funding will only be accepted for activities that align with our strategic priorities and charitable objectives.
Diversification: Where possible, we seek funding from multiple industry partners for each project to ensure balanced support.
Transparency: We are committed to being open, honest, and transparent about our relationships with industry partners, including in response to public or media enquiries.
Disclosure: We proactively declare any relevant conflicts of interest when submitting evidence or input to decision-making bodies such as the National Institute for Health and Care Excellence (NICE) and the Scottish Medicines Consortium (SMC).
Governance: Our Board of Trustees and Clinical Advisory Group remain fully independent. Any individual conflicts of interest must be openly declared and appropriately managed.
Compliance: All industry partnerships must comply with the Association of the British Pharmaceutical Industry (ABPI) Code of Practice or other relevant regulatory standards.